Govt slashes coronary stent prices by up to 400%
PTI In a major relief to patients, the government has reduced prices of coronary stents by up to 400 per cent, capping them at Rs 7,260 for bare metal ones and Rs 29,600 for the drug-eluting variety. The National Pharmaceutical Pricing Authority (NPPA) in a notification said in public interest, it has fixed the ceiling price of bare metal stents at 7,260 and that of drug-eluting stents and bioresorbable vascular scaffold (BVS)/biodegradable stents at Rs 29,600. A coronary stent is a tube-shaped device placed in the arteries that supply blood to the heart. It keeps the arteries open in the treatment of coronary heart diseases. The maximum retail cost of a stent currently ranges from Rs 25,000 to Rs 1.98 lakh. ...
Union Minister of Chemicals & Fertilizers launches Pharma Price Data Bank
Source: PIB, Government of India. The Union Minister for Chemicals and Fertilizers, Ananth Kumar addressing at the launch of the “Pharma Price Data Bank” an integrated Pharmaceutical Database management System (IPDM), in New Delhi on June 25, 2015. Source: PIB, Government of India. The Union Minister of Chemicals & Fertilizers, Ananth Kumar launched Pharma Price Data Bank on June 25, 2015. It is an integrated Pharmaceutical Database Management System, managed and operated by National Pharmaceutical Pricing Authority (NPPA). Speaking at the release ceremony, the Minister said that this is the first data bank of Pharma industry that will help the manufacturers, regulator as well as the common masses. He said that now manufacturers can fill their mandatory forms online, the Government ...
Centre examines overpricing and non-availability of drugs
The Dollar Business Bureau The Union Ministry of Chemicals and Fertilizers, on Tuesday, informed that the Special Committee recommendations are being examined for formulating a ‘Policy for Promotion of Manufacturing of Bulk Drugs’. The Union Minister Ananth Kumar informed Lok Sabha that a special Committee, under the chairmanship of Secretary, Department of Health Research, has been constituted to check the issues pertaining to the Active Pharmaceutical Ingredients (API). The Committee will check the whole issues of APIs by identifying the APIs of critical importance and will then work out on a package of interventions and procedures to build domestic production capabilities and further examine the cost implications, the Minister added. The recommendations made by the Committee include the ...
